For a pharma company, determining the relative GMP health of your manufacturing sites and of your CMO sites is a key element of quality risk management and continuous improvement and a key part of due diligence when evaluating potential GMP partners. Evaluation of the GMP health of a manufacturing site is based on many factors, some obvious and others subtle. This presentation will go through a methodology that uses publicly available information and produces a site risk analysis, including what the risk factors are, how to determine them, how to categorize them as critical, major, or minor, how weigh them to produce a composite score, and how to evaluate the signals over time. Included will be case studies of three pharma company manufacturing sites. It will also explore why some inspections do not detect issues while others at the same site may find serious issues.
Senior GMP Quality Expert at Redica Systems (formerly FDAzilla)
Formerly GMP Quality Expert at Clarke Solutions (now Verista) where I helped remediate GMP issues at 503B companies, including developing coursework on manufacturing deviation investigations and teaching the course to enable 503B personnel to properly conduct and document investigations.
Formerly, Chief Information Officer and Senior Editor at International Pharmaceutical Quality, www.ipqpubs.com, where I reported on and analyzed what was taking place "inside the global regulatory dialogue" and became an internationally known pharmaceutical journalist.
31 years at Lilly in technical and leadership positions in product development, manufacturing, plant quality, site quality, corporate quality, and quality systems, including the following:
Manager for four years in biosynthetic API manufacturing operations.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.